Related Experiment Video
Updated: Aug 6, 2026
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
microRNAs and long noncoding RNAs in heart failure: Biogenesis, subcellular functions, and clinical applications
Yuyan Tang1,2, Rong Xie1,2, Xiang Cheng3
1Department of Cardiology, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Chinese Medical Journal
|July 20, 2026
Summary
Novel microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) offer new therapeutic targets for heart failure. Understanding their subcellular functions can optimize treatments for cardiovascular diseases, improving patient outcomes.
Area of Science:
- Biomedical research
- Molecular biology
- Cardiology
Background:
- Cardiovascular diseases, particularly heart failure, are leading causes of death and disability.
- Established mechanisms include cardiomyocyte hypertrophy, cardiac fibrosis, and endothelial dysfunction.
- Current therapies have limited impact on heart failure mortality, necessitating new strategies.
Purpose of the Study:
- To review the diverse functions of subcellular microRNAs (miRNAs) and long non-coding RNAs (lncRNAs).
- To explore the clinical applications of miRNAs and lncRNAs in heart failure treatment.
- To highlight how subcellular localization influences miRNA and lncRNA functions and therapeutic potential.
Main Methods:
- Literature review of studies on miRNAs and lncRNAs in heart failure.
- Analysis of research on subcellular localization and regulatory roles of non-coding RNAs.
- Synthesis of current evidence on miRNA- and lncRNA-based therapeutic strategies.
Main Results:
- miRNAs and lncRNAs exhibit varied functions based on their subcellular locations.
- Subcellular functions provide insights into the pathogenesis of heart failure.
- miRNA- and lncRNA-based therapies show promise for optimizing heart failure treatment.
Conclusions:
- Subcellular miRNAs and lncRNAs represent a significant area for understanding heart failure.
- Targeting these non-coding RNAs based on their cellular functions offers novel therapeutic avenues.
- Further research into subcellular non-coding RNA functions is crucial for advancing heart failure treatment.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...